A customized mass array panel for BCR::ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia

INTRODUCTION: The therapeutic strategy and management of chronic myeloid leukemia (CML) have rapidly improved with the discovery of effective tyrosine kinase inhibitors (TKIs) to target BCR::ABL1 oncoprotein. However, nearly 30% of patients develop TKI resistance due to acquired mutations on the tyr...

Descripción completa

Detalles Bibliográficos
Autores principales: Limsuwanachot, Nittaya, Rerkamnuaychoke, Budsaba, Niparuck, Pimjai, Singdong, Roongrudee, Kongruang, Adcharee, Hirunpatrawong, Piyapha, Siriyakorn, Thanaporn, Yenchitsomanus, Pa-thai, Siriboonpiputtana, Teerapong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148036/
https://www.ncbi.nlm.nih.gov/pubmed/37128502
http://dx.doi.org/10.1016/j.jmsacl.2023.04.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148036/
https://www.ncbi.nlm.nih.gov/pubmed/37128502
http://dx.doi.org/10.1016/j.jmsacl.2023.04.002

Ejemplares similares